预约演示
更新于：2025-05-31
Desloratadine
地氯雷他定
更新于：2025-05-31
概要
基本信息
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C19H19ClN2 |
InChIKeyJAUOIFJMECXRGI-UHFFFAOYSA-N |
CAS号100643-71-8 |
关联
119
项与 地氯雷他定 相关的临床试验TCTR20240427007
A Bioequivalence study of a randomized, open-label, single dose, two-way crossover design with two-period, two-treatment and two-sequence of Desloratadine 5 mg tablets relative to Aerius 5 mg tablets, in healthy Thai volunteers under fasting condition.
NCT06916884
Confirmatory Study on the Efficacy and Safety of the Fixed-dose Combination of Desloratadine/Betamethasone Versus Desloratadine as Treatment in Patients With Allergic Rhinitis
CTR20243003
单中心、随机、开放、两周期交叉、单剂量空腹和餐后状态下的生物等效性试验
100 项与 地氯雷他定 相关的临床结果
登录后查看更多信息
100 项与 地氯雷他定 相关的转化医学
登录后查看更多信息
100 项与 地氯雷他定 相关的专利（医药）
登录后查看更多信息
1,696
项与 地氯雷他定 相关的文献（医药）2025-12-01European Journal of Trauma and Emergency Surgery
Increased use of damage control laparotomy for emergency small bowel or colon surgery: does it affect patient outcomes?
Article
作者: Wendt, Linder ; Skeete, Dionne A ; Ye, Maosong ; Huang, Kevin ; Littlefield, Connor P ; Galet, Colette
PURPOSE:
Evidence to guide the application of damage control laparotomy (DCL) in emergency surgery patients is limited. We assessed whether DCL use for emergent small bowel or colon surgery increased over time and its impact on outcomes. We hypothesized that DCL would be utilized more often in patients with significant comorbidities or septic shock with improved outcomes.
METHODS:
National Surgical Quality Improvement Program (NSQIP) data on DCL patients from 2014 to 2020 were used. Endpoints were incidence of DCL, in-hospital mortality, hospital length of stay (LOS), complications, and 30-day readmission over time. P-values < 0.05 were considered statistically significant.
RESULTS:
DCL incidence increased over time (OR = 1.07 [1.05-1.08], p < 0.001). Presence of pre-operative septic shock increased over the years (OR = 1.04 [1.01-1.07], p = 0.007). Mortality, readmission, and post-operative septic complications did not change over the study period. Average LOS significantly decreased over time (OR = 0.93 [0.92-0.95], p < 0.001).
CONCLUSION:
The odds of a surgeon using DCL increased by 7% each year. Although pre-operative septic shock incidence increased, LOS decreased over time while mortality remained unchanged.
2025-10-01TISSUE & CELL
Optimizing thrombospondin function through repositioning: Implications for injury and diabetic foot ulcer management
Article
作者: Rodriguez-Carlos, Adrian ; Trujillo-Paez, Juan Valentin ; Gonzalez-Curiel, Irma ; Gonzalez-Muñiz, Oscar ; Felix-Arellano, Camelia ; Rivas-Santiago, Bruno ; Jacobo-Delgado, Yolanda M
Diabetic foot ulcer (DFU) is a common and challenging complication of diabetes, characterized by impaired wound healing, chronic inflammation, poor tissue remodeling, and chronic inflammation. Thrombospondin 1 (TSP1) and thrombospondin 4 (TSP4) are key extracellular matrix proteins involved in wound healing. This study aimed to assess the levels and propose inducers of TSP1, TSP4, and SOD3 in diabetic foot ulcer. In this study, we first evaluated the expression of TSP1, TSP4, and superoxide dismutase 3 (SOD3) in DFU tissues using real-time PCR and immunohistochemistry. In DFU tissues using real-time PCR we found that TSP-4 expression was significantly reduced and confirmed by immunohistochemistry. TSP1 expression did not show similar alterations. Additionally, while SOD3 expression was decreased at the mRNA level in the diabetic population, no changes were observed in the protein levels by immunohistochemistry. To explore potential therapeutic approaches, we performed pharmacological repositioning and identified three drugs riboflavin, desloratadine, and chenodeoxycholic acid that selectively increased TSP-4 expression. These findings suggest that riboflavin, desloratadine, and chenodeoxycholic acid may promote wound healing in DFU by specifically upregulating TSP4, potentially enhancing tissue remodeling and angiogenesis.
2025-08-01FOOD CHEMISTRY
Investigation into the effects of acute heat stress on stress level, meat quality, myofibrillar proteins properties and serum metabolites release of Muscovy ducks (Cairina moschata)
Article
作者: Huang, Tianran ; Xiao, Mengchao ; Huang, Jichao ; Li, Zimu ; Zhu, Zongshuai ; Huang, Ming
This study systematically investigated the effects of acute heat stress (AHS) on Muscovy ducks, focusing on plasma stress indicators, meat quality, myofibrillar proteins (MPs) properties, and serum metabolite profiles. AHS significantly elevated stress level, impairing meat quality, as evidenced by higher L* value, shear force, drip loss, and cooking loss (P < 0.05). It also induced MPs oxidation and aggregation, reflected by elevated carbonyl content, turbidity, zeta potential, and particle size. MPs structural alterations were confirmed by fluorescence quenching and increased exposure of hydrophobic groups. Correlation analysis revealed strong associations between physicochemical changes and MPs oxidation. Metabolomic analysis identified 161 and 105 differential metabolites in the CON vs. LS and CON vs. SS comparisons, respectively, involving 25 metabolic pathways related to energy, amino acids, and fatty acids. These findings provide novel insights into the molecular pathways of AHS-induced meat quality deterioration and reveal potential intervention timing for the poultry industry.
100 项与 地氯雷他定 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 皮炎 | 日本 | 2016-09-28 | |
| 皮炎 | 日本 | 2016-09-28 | |
| 湿疹 | 日本 | 2016-09-28 | |
| 湿疹 | 日本 | 2016-09-28 | |
| 瘙痒 | 日本 | 2016-09-28 | |
| 常年性变应性鼻炎 | 澳大利亚 | 2003-05-28 | |
| 慢性荨麻疹 | 美国 | 2002-02-08 | |
| 季节性过敏性鼻炎 | 美国 | 2001-12-21 | |
| 过敏性鼻炎 | 欧盟 | 2001-01-15 | |
| 过敏性鼻炎 | 冰岛 | 2001-01-15 | |
| 过敏性鼻炎 | 列支敦士登 | 2001-01-15 | |
| 过敏性鼻炎 | 挪威 | 2001-01-15 | |
| 荨麻疹 | 欧盟 | 2001-01-15 | |
| 荨麻疹 | 冰岛 | 2001-01-15 | |
| 荨麻疹 | 列支敦士登 | 2001-01-15 | |
| 荨麻疹 | 挪威 | 2001-01-15 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 进行性脑脊髓炎伴僵硬 | 临床3期 | - | 2006-09-01 | |
| 鼻塞 | 临床3期 | - | 2003-12-01 | |
| 间歇性哮喘 | 临床3期 | - | 2003-05-01 | |
| 特应性皮炎 | 临床3期 | - | 2003-03-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | - | - | 积极 | 2020-02-15 | |||
临床3期 | 449 | (Desloratadine) | 繭鏇鬱築鹹願鹹顧衊鏇(鑰積積襯繭憲淵蓋製鑰) = 築壓積網鏇遞鑰鑰襯夢 憲鏇襯積繭餘獵餘憲壓 (積壓鹹壓構齋壓餘築鹹, 衊壓積築淵醖鹽鏇簾製 ~ 簾築簾憲廠鑰膚鏇鑰鑰) 更多 | - | 2016-05-30 | ||
Placebo (Placebo) | 繭鏇鬱築鹹願鹹顧衊鏇(鑰積積襯繭憲淵蓋製鑰) = 衊觸範積鬱範餘簾積夢 憲鏇襯積繭餘獵餘憲壓 (積壓鹹壓構齋壓餘築鹹, 壓選蓋膚顧蓋蓋選醖範 ~ 淵鹽顧遞襯製遞鹽衊範) 更多 | ||||||
临床3期 | 94 | 蓋顧壓蓋衊廠築窪蓋廠(願壓願願鬱築範獵範願) = 鏇繭遞膚簾構簾廠選廠 鏇醖鹹鹹遞鑰簾艱積齋 (積窪選廠壓鏇膚膚糧壓, 範簾遞鏇糧壓壓獵醖築 ~ 積壓築構餘築築淵繭築) 更多 | - | 2014-11-19 | |||
临床3期 | 239 | Placebo+Desloratadine (Desloratadine 5 mg) | 顧鹹窪襯顧顧鬱鏇獵範(築夢襯構選艱窪願獵壓) = 窪淵繭淵顧積膚構觸鑰 襯餘網餘襯遞顧築鏇艱 (積獵襯糧鹽繭糧繭範構, 衊獵構鹽襯網鹽齋鏇廠 ~ 夢鬱艱鏇觸網衊顧遞鬱) 更多 | - | 2014-10-30 | ||
(Desloratadine 10 mg) | 顧鹹窪襯顧顧鬱鏇獵範(築夢襯構選艱窪願獵壓) = 製夢遞壓網蓋築鹹鹹壓 襯餘網餘襯遞顧築鏇艱 (積獵襯糧鹽繭糧繭範構, 繭簾夢糧鹽簾網鹽淵蓋 ~ 築簾醖構餘構鹽網廠鑰) 更多 | ||||||
临床3期 | 716 | (5-mg Desloratadine Tablet) | 壓構鑰淵簾齋醖醖廠膚(積簾窪鏇夢製繭鬱淵壓) = 觸憲壓壓願構願鑰襯窪 顧範鹹夢廠糧願糧積構 (願積鏇願餘壓膚糧願顧, 0.13) 更多 | - | 2010-11-19 | ||
Placebo tablet (Placebo Tablet) | 壓構鑰淵簾齋醖醖廠膚(積簾窪鏇夢製繭鬱淵壓) = 獵鏇憲鹽淵蓋願憲製壓 顧範鹹夢廠糧願糧積構 (願積鏇願餘壓膚糧願顧, 0.12) 更多 | ||||||
临床4期 | 36 | Levocetirizine placebo capsule+Desloratadine (Desloratadine 5 mg Tablet + Levocetirizine Placebo Capsule) | 窪繭繭糧繭網衊選繭糧(壓蓋壓壓簾餘鏇鹹衊遞) = 範蓋鏇鏇網範壓繭構選 觸糧艱窪膚選餘壓壓壓 (繭鬱衊壓淵鬱積觸鬱艱, 1.65) 更多 | - | 2010-11-01 | ||
Desloratadine placebo tablet+levocetirizine (Desloratadine Placebo Tablet + Levocetirizine 5 mg Capsule) | 窪繭繭糧繭網衊選繭糧(壓蓋壓壓簾餘鏇鹹衊遞) = 鹹鹽壓鏇鑰遞壓簾選獵 觸糧艱窪膚選餘壓壓壓 (繭鬱衊壓淵鬱積觸鬱艱, 1.60) 更多 | ||||||
临床4期 | 233 | 衊獵鬱築憲積顧積鏇築(遞選淵顧襯衊顧襯鏇構) = 襯壓襯鹹憲醖構鏇選鏇 夢窪齋糧築製範夢獵繭 (夢襯衊遞築憲鏇壓憲鹽 ) | 积极 | 2009-09-01 | |||
Placebo | 衊獵鬱築憲積顧積鏇築(遞選淵顧襯衊顧襯鏇構) = 衊齋廠獵窪淵艱獵繭壓 夢窪齋糧築製範夢獵繭 (夢襯衊遞築憲鏇壓憲鹽 ) | ||||||
N/A | 122 | 壓獵夢積鑰衊製顧膚網(構蓋醖願壓窪築廠選繭) = Adverse events occurred in 16% of the children, were mild and transient and somnolence was the more common. 廠淵齋築簾鏇艱製壓窪 (構選觸願獵糧網憲餘憲 ) 更多 | - | 2009-03-15 | |||
临床3期 | 547 | (5-mg Desloratadine Tablet) | 網鏇齋衊壓夢淵蓋觸鏇(遞觸餘壓鏇壓廠糧簾艱) = 窪顧餘鹽窪衊鏇壓鏇製 糧艱淵製鑰齋鹹窪願蓋 (積鏇構夢憲餘繭築鹽範, 0.21) 更多 | - | 2009-03-06 | ||
Placebo (Placebo Tablet) | 網鏇齋衊壓夢淵蓋觸鏇(遞觸餘壓鏇壓廠糧簾艱) = 餘壓壓餘鏇構鹽鹽齋齋 糧艱淵製鑰齋鹹窪願蓋 (積鏇構夢憲餘繭築鹽範, 0.2) 更多 | ||||||
临床2期 | 137 | 鏇憲築鬱憲窪窪積網蓋(獵糧憲積膚遞願糧願夢) = 鹽壓衊簾築窪製蓋簾壓 築艱壓衊繭鑰鹽網鬱製 (憲鏇積窪襯鹽膚糧憲觸 ) 更多 | - | 2008-01-01 | |||
Placebo | 鏇憲築鬱憲窪窪積網蓋(獵糧憲積膚遞願糧願夢) = 衊壓廠積顧獵壓鬱糧鏇 築艱壓衊繭鑰鹽網鬱製 (憲鏇積窪襯鹽膚糧憲觸 ) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用